LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

Strona główna・Stock List・MannKind Corp

MannKind Corp

Open

SectorHealthcare

3.64 0.55

Buy Sell

Overview

Share price change

24h

Current

Min

3.54

Max

3.73

Key metrics
By Trading Economics
Income	-671K -17M
Sales	-22M 90M
P/E Sector Avg	140.5 50.102
EPS	-0.02
Profit margin	-18.431
Employees	591
EBITDA	5.9M 3.4M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+114.93% upside

Dividends
By Dow Jones
Next Earnings	5 sie 2026

Market Stats
By TradingEconomics
Market Cap	177M 1B
Previous open	3.09
Previous close	3.64

News Sentiment

By Acuity

67%

33%

295 / 344 Ranking in Healthcare

MannKind Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

28 maj 2026, 22:47 UTC

Earnings

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28 maj 2026, 20:45 UTC

Earnings

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28 maj 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28 maj 2026, 23:39 UTC

Market Talk

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28 maj 2026, 23:31 UTC

Market Talk

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28 maj 2026, 23:17 UTC

Market Talk

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28 maj 2026, 23:02 UTC

Market Talk

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28 maj 2026, 22:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28 maj 2026, 22:41 UTC

Market Talk

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28 maj 2026, 22:37 UTC

Market Talk

Acquisitions, Mergers, Takeovers

M&A-Related Insurance Payments In North America Rise -- Market Talk

28 maj 2026, 22:04 UTC

Acquisitions, Mergers, Takeovers

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28 maj 2026, 22:04 UTC

Acquisitions, Mergers, Takeovers

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28 maj 2026, 21:12 UTC

Earnings

Acquisitions, Mergers, Takeovers

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28 maj 2026, 21:00 UTC

Earnings

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28 maj 2026, 20:57 UTC

Earnings

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 maj 2026, 20:55 UTC

Earnings

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28 maj 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

28 maj 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

28 maj 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

28 maj 2026, 20:48 UTC

Hot Stocks

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28 maj 2026, 20:34 UTC

Earnings

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28 maj 2026, 20:31 UTC

Earnings

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28 maj 2026, 20:28 UTC

Earnings

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28 maj 2026, 20:26 UTC

Earnings

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 maj 2026, 20:20 UTC

Earnings

Costco 3Q Membership Fees $1.37B

28 maj 2026, 20:20 UTC

Earnings

Costco 3Q Net Sales $69.15B

28 maj 2026, 20:19 UTC

Earnings

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28 maj 2026, 20:19 UTC

Earnings

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28 maj 2026, 20:17 UTC

Earnings

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28 maj 2026, 20:17 UTC

Earnings

Costco 3Q Same-Store Sales Up 9.8% >COST

Peer Comparison

Price change

MannKind Corp Forecast

Price Target

By TipRanks

114.93% upside

12 Months Forecast

Average 7.63 USD 114.93%

High 10 USD

Low 4.75 USD

Based on 6 Wall Street analysts offering 12 month price targets forMannKind Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to MannKind Corp - Dist in the past 3 months.

Sentiment

By Acuity

295 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.